Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (4280)	3/9/1998 12:58:00 PM
From: squetch	Read Replies (1) \| Respond to of 9719

PB, I am not impressed w/ Allovectin and Leuvectin either. I found an article/interview w/ Dr. Victor McKusick, who is labeled as the founder of modern medical genetics. The article was in MIT Technology Review July 97. Here are McKusick's comments>>Despite all the hype about gene-replacement therapy, researchers are beginning to realize that it isn't going to happen soon enough for many medical conditions. Scientists have had a difficult time designing the vectors that carry replacement genes to where they need to go, and producing genes that both persist and function at a high enough level. If you know the steps that connect an abnormal gene to a disorder, by contrast, then you can often intervene along the way w/ appropriate drugs and essentially cure the condition<< His three most important trends in research linking genes to human illness 1) shift from looking at cause or precise genetic defect, to the mechanism by which disease is produced 2)study into complex diseases--involving more than one gene 3) the exciting effort to compare genomes of different species. Not earth shattering, but he knows more about it than I.(:>) Now to find the time to check the 200 LGND posts from this weekend. squetch